CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma.

Niklas KlümperDamian J RalserRomina ZarblKatrin SchlackAndres Jan SchraderMarc RehlinghausMichèle J HoffmannGünter NiegischAnnemarie UhligLutz TrojanJulie SteinestelKonrad SteinestelRalph M WirtzDanijel SikicMarkus EcksteinGlen KristiansenMarieta TomaMichael HölzelManuel RitterSebastian StriethJörg EllingerDimo Dietrich

Published in: Journal for immunotherapy of cancer (2022)

Our study suggests CTLA4 methylation as a powerful predictive biomarker for immunotherapy response in metastatic RCC.

Keyphrases

dna methylation
small cell lung cancer
squamous cell carcinoma
transcription factor
genome wide